Insitro, which uses machine learning to speed up drug discovery, raises $400M led by Canada Pension Plan; other investors include SoftBank, Temasek, and a16z
Hannah Kuchler / Financial Times :
Context & Ripple Effects
This round is the escalation point in insitro's funding arc: after its $143M Series B led by Andreessen Horowitz brought total raised to $243M in mid-2020, it now adds $400M in a single step, with the lead shifting from venture capital to Canada Pension Plan and participation from SoftBank and Temasek — crossover and sovereign capital moving into AI-native drug discovery.
The broader field was already crowding: Hong Kong-based Insilico Medicine extended its Series D to $95M in 2022, BioNTech chose acquisition over building when it bought InstaDeep for up to £562M in early 2023, and BenchSci raised CA$95M for pharma-facing discovery tooling. What came after validates where this round pointed — Boston-based Insilico's Series E at a $1B+ valuation and Isomorphic Labs' $600M DeepMind-spinoff raise, both landing within weeks of each other in March 2025.
First-order effects
- Insitro's war chest jumps from $243M total to roughly $643M on paper, giving it runway to push machine-learning-driven programs toward clinical validation while rivals are still Series D-sized.
- Andreessen Horowitz converts from sole Series B lead to minority participant, ceding pricing power in the round to Canada Pension Plan, SoftBank, and Temasek — a signal that long-duration capital now sets terms in this category.
Second-order effects
- Competitors must scale to match: Insilico Medicine kept raising through Series D and then a Series E at a $1B+ valuation, and DeepMind spun out Isomorphic Labs specifically to chase the same target with a larger raise — discovery AI becomes a capital-intensity contest, not a seed-stage one.
- Pharma buyers face a build-or-buy fork sharpened by these valuations; BioNTech's up-to-£562M InstaDeep acquisition is the template for incumbents buying capability outright rather than waiting for partners to mature.
Third-order effects
- If the pattern holds, AI drug discovery bifurcates into a handful of deeply capitalized platforms (insitro, Isomorphic Labs, Insilico) absorbing most late-stage dollars, with pension and sovereign wealth funds — not traditional VCs — as the marginal buyer of clinical-stage risk.
- That capital mix pulls the sector toward longer diligence horizons and eventual consolidation: platform-scale companies become acquisition targets or IPO candidates for pharma, repeating the InstaDeep dynamic at much larger check sizes.
The trend: AI drug discovery is consolidating into a small set of heavily capitalized platforms funded increasingly by pension and sovereign capital rather than conventional venture rounds.